Among the wonderful advantages of financial markets is that you do not need a wealth to start investment, and although strong companies attract the attention of investors and their stock prices rise, it is still possible to buy high -quality shares for $ 50 or less, and in the biotechnology sector, and there are two prominent example companies that have great growth capabilities such as Viking Therapeutics (Nasdaq: VKTX) and Exelixis (NASDAQ: Exel) These two companies can achieve huge returns for investors who start acquiring their shares now.
Viking Therapeutics .. A revolution in the weight loss drug market
Viking Therapeutics is a medium -sized vital technology company that seeks to make a strong effect in the weight loss drug market that grows very quickly, and last year the company announced positive results in the second stage of its main real estate VK2735 designated for subcutaneous injection, and it is now preparing to move to the third stage of clinical tests, and at the same time the company is working on developing an oral version of this treatment, which has recently started the second stage experiences yet Promising performance in the first stage last year.
The opportunity for Viking represents tremendous potential, especially given the success of the leading companies in this field, and it is true that the company does not need to achieve the same huge sales achieved by Wegovy and Zepbound, but its arrival at the “Block Paster” level will be a major achievement for a smaller company, and despite the crowded weight loss drug market, a few companies other than Eli Lilly are crowded And Novo Nordisk managed to achieve promising results similar to what VK2735 achieved in clinical tests.
Moreover, VIKING has several other ambitious projects, its VK2809 dedicated to the treatment of metabolism associated with metabolism (MASH) has achieved positive results in the middle stage of clinical trials, and the company is working to develop another drug to lose weight is still in the initial stages of research, indicating that it does not put all its bets in one product.
Of course, investing in Viking Therapeutics carries some risks as it is still without a product approved in the market, but given its promising innovations, its shares may increase significantly in the long run, and if you are a comfortable investor with market fluctuations, it may be worth starting with a small investment in its arrow that is currently trading at about $ 25 per share.
Exelixis .. A strong player in the cancer drug market
The oncology market is one of the largest and most competitive markets in the field of biotechnology, as it is dominated by major pharmaceutical companies, yet EXELIXIS, a relatively small company compared to the great players, managed to achieve important successes thanks to their focus on cancer treatments.
On March 26, the company announced that its pioneering drug CABOMETYX obtained new approval in the United States to treat advanced deaf neurological tumors, which enhances its position as one of the most important cancer drugs.
Cabometyx has been the main engine for EXLIXIS growth over the past years, and continues to achieve new successes, which helps the company to achieve increasing revenues and profits, and in 2024 the company’s revenues increased by 18.5% on an annual basis to reach 2.2 billion dollars, while the profits per share grew by 22% registered $ 2 per share.
The company also managed last year to get rid of a great danger that was threatening it, as it was fighting a legal battle against MSN Laboratories, which was seeking to launch a generic version of CabometyX, but won the case, which means that Exelixis will not face competition from this varnish medicine until 2030.
Until then, CabometyX revenues will continue to grow, especially since the drug is still the most used to treat renal cell cancer, which is the most common type of kidney cancer, and the drug is subject to more clinical trials, which may lead to additional approvals for new treatment indicators.
Besides the success of Cabometyx Exelixis develops new drugs, and seeks to find another drug that can become a major driver of growth just like CabometyX, and among its promising projects there is Zanzalintinib, which is currently undergoing the third stage experiments to treat colon and advanced rectal cancer, in addition to other drugs in the initial stages of development.
Thanks to the continuous performance of CabometyX and its strong production line, its ability to compete in the cancer drug market can be an Exelixis arrow an excellent option for long -term investment, and the stock is currently trading at a price of less than $ 37, which makes it accessible to investors who look forward to a strong opportunity at a reasonable price.
